Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

  1. Holmes, F.A.
  2. Moy, B.
  3. Delaloge, S.
  4. Chia, S.K.L.
  5. Ejlertsen, B.
  6. Mansi, J.
  7. Iwata, H.
  8. Gnant, M.
  9. Buyse, M.
  10. Barrios, C.H.
  11. Silovski, T.
  12. Šeparović, R.
  13. Bashford, A.
  14. Zotano, A.G.
  15. Denduluri, N.
  16. Patt, D.
  17. Gokmen, E.
  18. Gore, I.
  19. Smith, J.W.
  20. Loibl, S.
  21. Masuda, N.
  22. Tomašević, Z.
  23. Petráková, K.
  24. DiPrimeo, D.
  25. Wong, A.
  26. Martin, M.
  27. Chan, A.
  28. Erakutsi egile guztiak +
Aldizkaria:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Argitalpen urtea: 2023

Alea: 184

Orrialdeak: 48-59

Mota: Artikulua

DOI: 10.1016/J.EJCA.2023.02.002 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus